Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Sirish Dharmapuri, Umut Özbek, Hiren Jethra, Tomi Jun, Thomas U. Marron, Anwaar Saeed, Yi‐Hsiang Huang, Mahvish Muzaffar, Matthias Pinter, Lorenz Balcar, Claudia Angela Maria Fulgenzi, Suneetha Amara, Arndt Weinmann, Nicola Personeni, Bernhard Scheiner, Tiziana Pressiani, Musharraf Navaid, Bertram Bengsch, Sonal Paul, Uqba Khan, Dominik Bettinger, Naoshi Nishida, Yehia I. Mohamed, Arndt Vogel, Anuhya Gampa, James Korolewicz, Antonella Cammarota, Ahmed O. Kaseb, Peter R. Galle, Anjana Pillai, Yinghong Wang, Alessio Cortellini, Masatoshi Kudo, Antonio D’Alessio, Lorenza Rimassa, David J. Pinato, Celina Ang (2023). Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. , 15(11), DOI: https://doi.org/10.4251/wjgo.v15.i11.1900.
Article22 days agoPreliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Vincent E. Gaillard, Anwaar Saeed, Brooke Wietharn, Hannah Hildebrand, Linda Y. Wu, Celina Ang, Thomas U. Marron, Arndt Weinmann, Peter R. Galle, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Pei‐Chang Lee, Yi‐Hsiang Huang, Suneetha Amara, Mahvish Muzaffar, Abdul Rafeh Naqash, Antonella Cammarota, Nicola Personeni, Tiziana Pressiani, Rohini Sharma, Matthias Pinter, Alessio Cortellini, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato (2022). Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study. , 76(4), DOI: https://doi.org/10.1002/hep.32468.
Article22 days agoNeutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).
Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Hong Jae Chon, Masatoshi Kudo, Martin Schönlein, Johann von Felden, Brooke Wietharn, Samuel Phen, Bernhard Scheiner, Lorenz Balcar, Yi‐Hsiang Huang, Tiziana Pressiani, Gianluca Masi, Abdul Rafeh Naqash, Dominik Bettinger, Arndt Vogel, Peter R. Galle, Vince Gaillard, Celina Ang (2023). Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).. , 41(4_suppl), DOI: https://doi.org/10.1200/jco.2023.41.4_suppl.504.
Article22 days agoThe ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab
Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Jaekyung Cheon, Naoshi Nishida, Celina Ang, Thomas U. Marron, Linda Y. Wu, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Matthias Pinter, Lorenz Balcar, Yi‐Hsiang Huang, Aman Mehan, Samuel Phen, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schoenlein, Johann von Felden, Kornelius Schulze, Henning Wege, Adel Samson, Peter R. Galle, Masatoshi Kudo, Alessio Cortellini, Amit G. Singal, Lorenza Rimassa, Rohini Sharma, Hong Jae Chon, David J. Pinato (2023). The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab. , 78, DOI: https://doi.org/10.1016/s0168-8278(23)01373-9.
Article22 days agoImpact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Anwaar Saeed, Brooke Wietharn, Hannah Hildebrand, Linda Y. Wu, Celina Ang, Thomas U. Marron, Arndt Weinmann, Peter R. Galle, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Pei‐Chang Lee, Yi‐Hsiang Huang, Suneetha Amara, Mahvish Muzaffar, Abdul Rafeh Naqash, Antonella Cammarota, Nicola Personeni, Tiziana Pressiani, Matthias Pinter, Alessio Cortellini, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Rohini Sharma (2022). Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. , 42(11), DOI: https://doi.org/10.1111/liv.15405.
Article22 days ago